Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Janssen Biotech, Inc. v. Amgen Inc.
Case Number:
1:22-cv-01549
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 23, 2023
Janssen And Amgen Settle Patent Row Over Stelara Biosimilar
Janssen and Amgen told a Delaware federal judge Monday they've agreed to settle a dispute over Janssen's attempt to block Amgen from launching a copycat version of its blockbuster immunosuppressive product Stelara, which treats conditions like ulcerative colitis and Crohn's disease, according to a notice filed Monday.
-
March 02, 2023
J&J Page-Limit Flub Stifles Amgen Injunction, For Now
A Delaware federal judge on Thursday rejected Janssen Biotech's bid to block Amgen from launching its own version of the blockbuster immunosuppressive product Stelara while the parties' patent dispute plays out, saying the Johnson & Johnson subsidiary filed its overly long brief less than 10 minutes after asking the court's permission.
-
November 30, 2022
J&J Says Amgen Biosimilar Infringes Patents For $9B Product
Janssen is urging a Delaware federal court to block Amgen from allegedly launching a copycat version of its blockbuster immunosuppressive product Stelara, saying the biosimilar would infringe a pair of patents.